Core Viewpoint - The article emphasizes the rising prevalence of gestational diabetes in China, which has reached 17.5%, and aims to clarify common misconceptions while providing practical knowledge for expectant mothers to manage this condition effectively [2]. Group 1: Prevalence and Awareness - The incidence of gestational diabetes in China is currently at 17.5%, meaning 1 in every 6 pregnant women is affected [2]. - The increase in cases is attributed to the relaxation of the two-child and three-child policies and a higher proportion of older pregnant women [2]. - There is a significant lack of awareness among the public regarding gestational diabetes, leading to either excessive anxiety or negligence, both of which can adversely affect maternal and infant health [2]. Group 2: Common Concerns - Expectant mothers often have five main concerns regarding gestational diabetes, including the necessity of screening despite the absence of symptoms, the need for insulin treatment, dietary management, potential impacts on the baby, and post-delivery health [3][4][5][6][7][8]. Group 3: Misconceptions - Misconception 1: Only overweight mothers can develop gestational diabetes; however, slim mothers can also be at risk due to factors like genetics and age [11]. - Misconception 2: Fruits are healthy and can be consumed freely; in reality, the type and quantity of fruit matter, with high-sugar fruits needing to be limited [12]. - Misconception 3: Reducing carbohydrate intake is essential for controlling blood sugar; however, carbohydrates are crucial for fetal brain development, and a balanced intake is necessary [13]. - Misconception 4: Bed rest is the only option for managing gestational diabetes; moderate exercise is beneficial unless contraindicated by obstetric conditions [14]. Group 4: Management Strategies - A five-step management approach is recommended for expectant mothers diagnosed with gestational diabetes, including regular blood sugar monitoring, personalized dietary planning, post-meal physical activity, adherence to medical advice regarding medication, and maintaining a positive mindset [15][16][17].

Core Insights - The incidence of gestational diabetes mellitus (GDM) has significantly increased due to rising living standards and the growing number of older pregnant women, which can lead to adverse outcomes for both mothers and infants [1][2] Group 1: Definition and Causes - GDM occurs when a woman without diabetes develops glucose metabolism abnormalities during pregnancy, primarily influenced by hormonal changes and increased glucose demand as the fetus grows [1] - Risk factors for GDM include age ≥ 35, obesity, polycystic ovary syndrome, history of delivering large babies, and family history of diabetes [1] Group 2: Impacts on Maternal and Infant Health - GDM can lead to serious complications for mothers, including increased risks of miscarriage, pregnancy-induced hypertension, and delivery complications [1] - Infants born to mothers with GDM face higher risks of macrosomia, fetal growth restriction, congenital malformations, and preterm birth, as well as increased likelihood of respiratory distress syndrome, hypoglycemia, and neonatal jaundice [1] Group 3: Screening and Management - Screening for GDM is recommended through an oral glucose tolerance test (OGTT) between 24 to 28 weeks of pregnancy due to the typically hidden and atypical symptoms [2] - Effective blood sugar control during pregnancy is crucial, with specific targets for fasting and postprandial blood glucose levels outlined [2] - Management of GDM involves a combination of dietary control, exercise, medication, psychological support, and self-monitoring of blood glucose, with particular attention to energy intake and safe exercise practices [2]

Core Insights - The article discusses the impact of intrauterine hyperglycemia (IUHG) on the development of primordial germ cells (PGC) and fertility, particularly emphasizing its detrimental effects on female offspring [2][5][8] - A recent study published in Cell Discovery reveals that IUHG disrupts sex-specific epigenetic reprogramming during PGC development, leading to reproductive health issues and intergenerational effects [2][8] Group 1: Research Findings - IUHG significantly disrupts the development of PGCs, with a more pronounced effect on female offspring, resulting in reduced fertility [5][8] - The study utilized transgenic mice exposed to high glucose environments to systematically investigate the effects of IUHG on PGC development, revealing that IUHG affects chromatin accessibility and DNA methylation reprogramming in a sex-specific manner [5][6] Group 2: Mechanisms of Impact - In female embryos, IUHG leads to abnormal retention of chromatin accessibility at pluripotency gene promoters, inhibiting normal gene silencing and blocking the initiation of meiosis, ultimately hindering oocyte maturation [6][8] - In contrast, male embryos experience less severe effects on chromatin accessibility and gene transcription, but global DNA methylation reprogramming is impaired, particularly in key imprinted gene regions, indicating potential developmental impacts on future generations [6][8] Group 3: Implications and Future Directions - The findings underscore the importance of blood sugar management during pregnancy and suggest new avenues for improving reproductive health in offspring through metabolic intervention or epigenetic regulation [8]

Core Viewpoint - The article discusses the safety concerns and recommendations regarding the use of GLP-1 medications during pregnancy and breastfeeding, highlighting the need for caution and further research in this area [1][3]. Group 1: Research on GLP-1 Medications and Pregnancy - A large study published in January 2024 in JAMA Internal Medicine tracked around 50,000 children born to mothers with type 2 diabetes who used GLP-1 or insulin in early pregnancy, finding no increased risk of congenital defects compared to insulin use [5]. - Another study published in 2023 reviewed 39 independent studies on the effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and breastfeeding, concluding that there is extremely limited information on their safety [6]. Group 2: Risks Associated with GLP-1 Use During Pregnancy - Potential risks of GLP-1 medications during pregnancy may include miscarriage, low birth weight, and congenital defects, primarily due to their impact on maternal food intake and weight gain [6][7]. - Although concerns are mainly based on animal studies, the lack of human research has led to recommendations for discontinuation during pregnancy [7]. Group 3: Recommendations for Women Planning to Become Pregnant - Women are advised to stop using any GLP-1 medications at least two months before attempting to conceive, along with adopting additional preconception lifestyle measures [8]. - The American Diabetes Association recommends insulin as the preferred medication for managing diabetes during pregnancy, while other diabetes medications like metformin and glipizide are not first-line treatments due to their placental transfer [7][8]. Group 4: Breastfeeding Considerations - There is insufficient research to determine the safety of GLP-1 medications during breastfeeding, leading to recommendations against their use during this period [9][10].